About TearLab Corporation (OTCMKTS:TEAR)
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.
Industry, Sector and Symbol
Industry Glasses, Spectacles & Contact lenses
SymbolOTCMKTS:TEARPrevious Symbol: NASDAQ:TEAR
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$28.01 million
Price / Sales0.15
Price / CashN/A
Book Value($2.99) per share
Price / Book-0.24
Return on EquityN/A
Return on Assets-75.54%
Frequently Asked Questions for TearLab Corporation (OTCMKTS:TEAR)
What is TearLab Corporation's stock symbol?
TearLab Corporation trades on the OTCMKTS under the ticker symbol "TEAR."
When did TearLab Corporation's stock split? How did TearLab Corporation's stock split work?
Shares of TearLab Corporation reverse split before market open on Friday, February 24th 2017. The 1-10 reverse split was announced on Friday, February 24th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 23rd 2017. An investor that had 100 shares of TearLab Corporation stock prior to the reverse split would have 10 shares after the split.
How were TearLab Corporation's earnings last quarter?
TearLab Corporation (OTCMKTS:TEAR) issued its earnings results on Monday, November, 13th. The medical research company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.06. The medical research company earned $6.52 million during the quarter, compared to analysts' expectations of $6.80 million. View TearLab Corporation's Earnings History.
When will TearLab Corporation make its next earnings announcement?
Where is TearLab Corporation's stock going? Where will TearLab Corporation's stock price be in 2017?
4 brokers have issued twelve-month price objectives for TearLab Corporation's shares. Their predictions range from $4.00 to $9.00. On average, they expect TearLab Corporation's stock price to reach $5.75 in the next year. View Analyst Ratings for TearLab Corporation.
Who are some of TearLab Corporation's key competitors?
Some companies that are related to TearLab Corporation include Bio Blast Pharma (ORPN), ESSA Pharma (EPIX), Dextera Surgical (DXTR), Mateon Therapeutics (MATN), Lombard Medical (EVARF), Secure Point Technologies (IMSC), Strata Skin Sciences (SSKN), Windtree Therapeutics (WINT), NeuroMetrix (NURO), Rosetta Genomics (ROSG), Affymax (AFFY), TetraLogic Pharmaceuticals Corporation (TLOG), Delcath Systems (DCTHD), BG Medicine (BGMD), M Pharmaceutical (MPHMF), Echo Therapeutics (ECTE) and IMRIS (IMRSQ).
Who are TearLab Corporation's key executives?
TearLab Corporation's management team includes the folowing people:
- Elias Vamvakas, Chairman of the Board (Age 58)
- Joseph S. Jensen, President, Chief Executive Officer, Chief Operating Officer, Director (Age 45)
- Wes Brazell, Chief Financial Officer (Age 51)
- Raymond Kong, Vice President - Sales
- Anthony E. Altig, Independent Director (Age 61)
- Thomas N. Davidson Jr., Independent Director (Age 57)
- Adrienne L. Graves Ph.D., Independent Director (Age 63)
- Paul M. Karpecki, Independent Director (Age 49)
- Richard L. Lindstrom M.D., Independent Director (Age 69)
How do I buy TearLab Corporation stock?
Shares of TearLab Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TearLab Corporation's stock price today?
One share of TearLab Corporation stock can currently be purchased for approximately $0.72.
How big of a company is TearLab Corporation?
TearLab Corporation has a market capitalization of $4.10 million and generates $28.01 million in revenue each year. The medical research company earns $-19,920,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. TearLab Corporation employs 75 workers across the globe.
How can I contact TearLab Corporation?
TearLab Corporation's mailing address is 9980 Huennekens Street Suite 100, San Diego CA, 92121. The medical research company can be reached via phone at 858-455-6006 or via email at [email protected]
MarketBeat Community Rating for TearLab Corporation (TEAR)MarketBeat's community ratings are surveys of what our community members think about TearLab Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for TearLab Corporation (OTCMKTS:TEAR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$5.75|
Consensus Price Target History for TearLab Corporation (OTCMKTS:TEAR)
Analysts' Ratings History for TearLab Corporation (OTCMKTS:TEAR)
(Data available from 11/24/2015 forward)
|8/15/2017||HC Wainwright||Reiterated Rating||Buy||$4.00|
|5/16/2017||Rodman & Renshaw||Lower Price Target||Buy -> Buy||$12.00 -> $4.00|
|3/11/2017||Craig Hallum||Set Price Target||Buy||$6.00|
|3/11/2017||Feltl & Co.||Downgrade||Strong-Buy -> Buy||$9.00|
|8/4/2016||Roth Capital||Downgrade||Buy -> Neutral|
|3/9/2016||Canaccord Genuity||Reiterated Rating||Buy|
Earnings History and Estimates Chart for TearLab Corporation (OTCMKTS:TEAR)
Earnings History by Quarter for TearLab Corporation (OTCMKTS TEAR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/8/2018|| || || || || || || || |
|11/13/2017||Q3 2017||($0.73)||($0.67)||$6.80 million||$6.52 million||View||N/A|
|8/14/2017||Q2 2017||($0.75)||($0.68)||$6.86 million||$7.00 million||View||N/A|
|5/15/2017||Q1 2017||($0.75)||($0.82)||$7.02 million||$6.70 million||View||N/A|
|3/9/2017||Q4 2016||($0.90)||($0.81)||$7.71 million||$7.12 million||View||Listen|
|11/7/2016||Q316||($0.08)||($0.07)||$7.13 million||$20.90 million||View||Listen|
|8/3/2016||Q2||($0.08)||($0.08)||$6.95 million||$6.90 million||View||N/A|
|5/4/2016||Q1||($0.23)||($0.21)||$6.53 million||$6.80 million||View||N/A|
|3/8/2016||Q4||($0.25)||($0.26)||$6.83 million||$6.80 million||View||N/A|
|11/5/2015||Q315||($0.24)||($0.24)||$6.40 million||$6.60 million||View||N/A|
|8/6/2015||Q215||($0.25)||($0.24)||$5.72 million||$6.30 million||View||N/A|
|5/7/2015||Q115||($0.21)||($0.25)||$5.40 million||$5.40 million||View||N/A|
|3/12/2015||Q414||($0.17)||($0.21)||$5.50 million||$5.30 million||View||N/A|
|11/5/2014||Q214||($0.17)||($0.17)||$5.50 million||$5.20 million||View||N/A|
|8/7/2014||Q114||($0.16)||($0.17)||$5.12 million||$9.20 million||View||N/A|
|5/8/2014||Q1||($0.14)||($0.17)||$4.76 million||$4.21 million||View||N/A|
|3/13/2014||Q413||($0.13)||($0.13)||$4.49 million||$4.40 million||View||N/A|
|11/12/2013||Q3||($0.14)||($0.13)||$3.80 million||$4.20 million||View||Listen|
|5/13/2013||Q1 2013||($0.12)||($0.30)||$2.18 million||$2.47 million||View||N/A|
Earnings Estimates for TearLab Corporation (OTCMKTS:TEAR)
Current Year EPS Consensus Estimate: $-2.64 EPS
Next Year EPS Consensus Estimate: $-1.36 EPS
Dividend History for TearLab Corporation (OTCMKTS:TEAR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for TearLab Corporation (OTCMKTS TEAR)
Insider Ownership Percentage: 12.00%
Institutional Ownership Percentage: 19.78%
Insider Trades by Quarter for TearLab Corporation (OTCMKTS TEAR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/30/2017||Awm Investment Company, Inc.||Major Shareholder||Sell||327,674||$3.20||$1,048,556.80|| |
|5/31/2016||Brock Wright||Director||Buy||59,686||$0.78||$46,555.08|| |
|5/26/2016||Brock Wright||Director||Buy||130,314||$0.76||$99,038.64|| |
|12/4/2014||Elias Vamvakas||CEO||Buy||50,000||$2.24||$112,000.00|| |
|11/18/2014||Elias Vamvakas||CEO||Buy||31,187||$2.55||$79,526.85|| |
|11/17/2014||Elias Vamvakas||CEO||Buy||18,813||$2.55||$47,973.15|| |
|11/11/2014||Elias Vamvakas||CEO||Buy||150,000||$2.49||$373,500.00|| |
|11/10/2014||Elias Vamvakas||CEO||Buy||16,276||$2.50||$40,690.00|| |
|11/10/2014||Joseph Jensen||COO||Buy||43,375||$2.31||$100,196.25|| |
|8/20/2014||Brock Wright||Director||Buy||23,000||$3.82||$87,860.00|| |
|8/19/2014||Brock Wright||Director||Buy||11,354||$3.83||$43,485.82|| |
|8/12/2014||Elias Vamvakas||CEO||Buy||70,000||$3.43||$240,100.00|| |
|6/30/2014||Richard Lindstrom||Director||Sell||5,000||$4.61||$23,050.00|| |
|5/13/2014||Elias Vamvakas||CEO||Buy||30,000||$3.99||$119,700.00|| |
|5/13/2014||Joseph Jensen||COO||Buy||48,693||$4.11||$200,128.23|| |
|4/1/2014||Paul Karpecki||Director||Sell||5,000||$6.83||$34,150.00|| |
|1/2/2014||Paul Karpecki||Director||Sell||5,000||$9.47||$47,350.00|| |
|12/31/2013||Richard Lindstrom||Director||Sell||5,000||$9.26||$46,300.00|| |
|11/15/2013||Richard Lindstrom||Director||Sell||5,000||$8.95||$44,750.00|| |
|10/11/2013||Paul Karpecki||Director||Sell||5,000||$10.96||$54,800.00|| |
|9/3/2013||William Dumencu||CFO||Sell||7,000||$13.22||$92,540.00|| |
|8/1/2013||William Dumencu||CFO||Sell||7,000||$14.39||$100,730.00|| |
|7/1/2013||Paul Karpecki||Director||Sell||5,000||$10.62||$53,100.00|| |
|7/1/2013||William Dumencu||CFO||Sell||7,000||$10.61||$74,270.00|| |
|6/3/2013||William Dumencu||CFO||Sell||7,000||$11.35||$79,450.00|| |
|4/2/2013||Tom Jr. Davidson||Director||Buy||1,500||$6.63||$9,945.00|| |
Latest Headlines for TearLab Corporation (OTCMKTS TEAR)
TearLab Corporation (OTCMKTS TEAR) Chart for Friday, November, 24, 2017